Assessing blood brain barrier damage in acute ischemic stroke patients
The Level of Blood Brain Barrier Damage Biomarker Predicting Hemorrhagic Transformation Following Acute Ischemic Stroke
This study is testing if measuring certain blood markers can help predict the risk of bleeding in the brain for adults who have had an acute ischemic stroke.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Capital Medical University Academic / other |
| Locations | 1 site (Beijin, XI Cheng District) |
| Trial ID | NCT05321225 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between blood brain barrier (BBB) damage and the risk of hemorrhagic transformation in patients with acute ischemic stroke. It aims to measure the levels of BBB damage biomarkers, such as serum occludin, to determine their predictive value for intracranial hemorrhage following ischemic events. The study will enroll patients aged 18-80 who have experienced an acute ischemic stroke and will analyze their blood samples for biomarker levels. The findings could provide insights into the pathophysiological mechanisms underlying complications in stroke patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-80 who have been diagnosed with acute ischemic stroke.
Not a fit: Patients with hemorrhagic stroke, tumor stroke, or those with recent serious head trauma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify patients at higher risk for hemorrhagic transformation, allowing for better management and treatment strategies.
How similar studies have performed: Other studies have explored the role of blood brain barrier integrity in stroke outcomes, suggesting that this approach has potential but may still be novel in this specific context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Enrolled patients aged 18-80years. 2. Acute ischemic stroke 3. Informed consent obtained. Exclusion Criteria: 1. Tumor stroke or hemorrhagic stroke or hemorrhagic cerebral infarction on admission. 2. Stroke or serious head trauma within the previous 3 months 3. inflammatory or infectious diseases, cancer, coagulation disturbance disease and severe renal and liver failure 4. blood sample occurred hemolysis or cloudy. 5. Incomplete clinical data 6. Platelet count of less than 100,000 per cubic millimeter 7. Received oral anticoagulation therapy preceding the onset of stroke and INR greater than 1.7 or prothrombin times greater than 15 seconds 8. Pregnant or breast-feeding women 9. Patients being enrolled or having been enrolled in other clinical trial -
Where this trial is running
Beijin, XI Cheng District
- Xuanwu hospital;Capital Medical University — Beijin, XI Cheng District, China (Recruiting)
Study contacts
- Principal investigator: Ke Jian Liu, PhD — Xuan Wu Hospital,Capital Medical University
- Study coordinator: xunming ji, MD PhD
- Email: jixunming@vip.163.com
- Phone: 86-10-83198952
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.